Wang Chengshuo, Cheng Lei, Li Huabin, Liu Zheng, Lou Hongfei, Shi Jianbo, Sun Ying, Wang Dehui, Yang Qintai, Yu Hongmeng, Zhao Changqing, Zhu Dongdong, Cheng Fengli, Li Yan, Liao Bo, Lu Meiping, Meng Cuida, Shen Shen, Sun Yueqi, Zheng Rui, Zhang Luo
Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Beijing Laboratory of Allergic Diseases and Beijing Key Laboratory of Nasal Diseases, Beijing Institute of Otolaryngology, Beijing, China.
J Thorac Dis. 2021 Nov;13(11):6217-6229. doi: 10.21037/jtd-21-1142.
Corticosteroids are efficacious in treating chronic rhinosinusitis (CRS), but concerns on the potential side effects remain, especially for long-term usage of systemic corticosteroids. Accumulated evidence shows that transnasal nebulization may be a reasonable solution in balancing both efficacy and safety. However, no consensus or guideline has been formulated on the use of steroid transnasal nebulization in treating CRS. The consensus is achieved through literature review and exchange of Chinese experts in Group of Otorhinolaryngology and Ophthalmology, Chinese Society of Allergy (CSA). This document covers the development, equipment, pharmacological mechanism, and evidence-based efficacy and safety, as well as the special concern of the application of steroid transnasal nebulization during the coronavirus disease (COVID-19) pandemic. The expert consensus clarifies the application of steroid transnasal nebulization in treating CRS and common comorbidities during the perioperative and postoperative periods.
皮质类固醇在治疗慢性鼻-鼻窦炎(CRS)方面有效,但对其潜在副作用的担忧依然存在,尤其是全身用皮质类固醇的长期使用。越来越多的证据表明,经鼻雾化可能是平衡疗效与安全性的合理解决方案。然而,关于类固醇经鼻雾化治疗CRS的使用,尚未形成共识或指南。本共识是通过中华医学会变态反应学分会鼻眼科学组的中国专家进行文献回顾和交流达成的。本文档涵盖了类固醇经鼻雾化的发展、设备、药理机制、循证疗效与安全性,以及在冠状病毒病(COVID-19)大流行期间类固醇经鼻雾化应用的特殊关注点。专家共识明确了类固醇经鼻雾化在围手术期和术后治疗CRS及常见合并症中的应用。